For example, Ang II-mediated cardiac hypertrophy is reported to occur via Src-dependent EGFR transactivation through AKT and ERK pathways that can be reversed with pharmacological inhibitors of EGFR (Liang et al., 2015; Peng et al., 2016). Here, SRC is linked to cardiac hypertrophy.